Metabolomics with baseline fasting plasma could predict transition from gestational diabetes to T2DM
THURSDAY, June 30, 2016 (HealthDay News) — A metabolomics signature can predict the transition from gestational diabetes mellitus (GDM) to type 2 diabetes (T2D), according to a study published online June 23 in Diabetes.
Amina Allalou, from the University of Toronto, and colleagues enrolled a prospective cohort of 1,035 women with GDM pregnancy at six to nine weeks postpartum and screened them for two years for T2D.
The researchers found that 113 of the 1,010 women without T2D at baseline progressed to T2D within two years, and another 17 developed T2D between two and four years. Metabolomics were conducted with baseline fasting plasma in a nested case-control study involving 122 incident T2D cases matched to non-cases by age, pre-pregnancy body mass index, and race/ethnicity. Twenty-one metabolites that differed significantly by incident T2D status were identified. Machine learning optimization was able to predict T2D incidence with a discriminative power of 83.0 and 76.9 percent in the training set and an independent testing set, respectively.
“Our metabolomics signature predicted T2D incidence from a single fasting sample,” the authors write. “This study represents the first metabolomics study of the transition from GDM to T2D validated in an independent testing set, facilitating early intervention.”
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
